C4 Therapeutics, Inc.

NasdaqGS:CCCC Voorraadrapport

Marktkapitalisatie: US$396.0m

C4 Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

C4 Therapeutics has a total shareholder equity of $242.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $376.1M and $133.4M respectively.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$255.64m
AandelenUS$242.66m
Totaal verplichtingenUS$133.40m
Totaal activaUS$376.06m

Recente financiële gezondheidsupdates

Recent updates

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Oct 02
We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

Aug 09
Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Aug 03
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12
Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29
Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03
New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14
Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10
Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 04

Analyse van de financiële positie

Kortlopende schulden: CCCC's short term assets ($273.2M) exceed its short term liabilities ($43.3M).

Langlopende schulden: CCCC's short term assets ($273.2M) exceed its long term liabilities ($90.1M).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: CCCC is debt free.

Schuld verminderen: CCCC had no debt 5 years ago.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: CCCC has sufficient cash runway for more than 3 years based on its current free cash flow.

Voorspelling contante baan: CCCC has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 23.5% each year.


Ontdek gezonde bedrijven